HK1100175A1 - substituted oxindol derivatives and medicaments containing the same - Google Patents

substituted oxindol derivatives and medicaments containing the same

Info

Publication number
HK1100175A1
HK1100175A1 HK07105667A HK07105667A HK1100175A1 HK 1100175 A1 HK1100175 A1 HK 1100175A1 HK 07105667 A HK07105667 A HK 07105667A HK 07105667 A HK07105667 A HK 07105667A HK 1100175 A1 HK1100175 A1 HK 1100175A1
Authority
HK
Hong Kong
Prior art keywords
alkylene
alkyl
oxo
chloro
optionally substituted
Prior art date
Application number
HK07105667A
Other languages
English (en)
Inventor
Wilfried Lubisch
Thorsten Oost
Wolfgang Wernet
Liliane Unger
Wilfried Hornberger
Herve Geneste
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of HK1100175A1 publication Critical patent/HK1100175A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07105667A 2004-07-13 2007-05-29 substituted oxindol derivatives and medicaments containing the same HK1100175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58740704P 2004-07-13 2004-07-13
DE102004033834A DE102004033834A1 (de) 2004-07-13 2004-07-13 Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
PCT/EP2005/007631 WO2006005609A2 (fr) 2004-07-13 2005-07-13 Derives d'oxindole substitues, et medicaments les renfermant

Publications (1)

Publication Number Publication Date
HK1100175A1 true HK1100175A1 (en) 2007-09-07

Family

ID=35530128

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105667A HK1100175A1 (en) 2004-07-13 2007-05-29 substituted oxindol derivatives and medicaments containing the same

Country Status (16)

Country Link
US (2) US7951807B2 (fr)
EP (1) EP1773814B1 (fr)
JP (1) JP2008506647A (fr)
KR (1) KR100873319B1 (fr)
CN (1) CN101018778A (fr)
AT (1) ATE377595T1 (fr)
AU (1) AU2005261867B2 (fr)
BR (1) BRPI0513281A (fr)
CA (1) CA2573404C (fr)
DE (2) DE102004033834A1 (fr)
ES (1) ES2297755T3 (fr)
HK (1) HK1100175A1 (fr)
IL (1) IL180654A0 (fr)
MX (1) MX2007000505A (fr)
NZ (1) NZ552578A (fr)
WO (1) WO2006005609A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
DE102004033834A1 (de) * 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
JP5125501B2 (ja) * 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物
DE102005014904A1 (de) 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
TWI403508B (zh) * 2006-08-26 2013-08-01 Abbott Gmbh & Co Kg 經取代苯并咪唑酮衍生物、包含其之醫藥品及其用途
DE102006040915A1 (de) * 2006-08-26 2008-03-20 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
WO2008080970A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme ligand du récepteur de la vasopressine
WO2008080972A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme modulateur du récepteur de la vasopressine
WO2008080971A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme ligand du récepteur de la vasopressine
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008107399A1 (fr) 2007-03-02 2008-09-12 Abbott Gmbh & Co. Kg Composés oxindoles substitués
JP5595926B2 (ja) * 2007-12-07 2014-09-24 アボット ゲーエムベーハー ウント カンパニー カーゲー ５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
WO2009071691A2 (fr) * 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Dérivés oxindoliques et leur utilisation comme médicament
SG188781A1 (en) 2007-12-27 2013-04-30 Abbott Gmbh & Co Kg Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
FR2927625B1 (fr) * 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
WO2010138600A2 (fr) 2009-05-29 2010-12-02 Abbott Laboratories Compositions pharmaceutiques utilisées dans le traitement de la douleur
CA2763931A1 (fr) * 2009-06-10 2010-12-16 Abbott Gmbh & Co. Kg Utilisation de derives substitues de l'oxindole pour le traitement et la prophylaxie de la douleur
DE102013102407B4 (de) * 2013-03-11 2021-12-30 Thyssenkrupp Industrial Solutions Ag Schaufelrad zum Abbau von Materialien aus einem Materialverband hoher Härte
CA2903141A1 (fr) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Derives d'oxindole a substituant oxetane et leur utilisation pour le traitement de maladies liees a la vasopressine
US9273036B2 (en) 2013-03-14 2016-03-01 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
US9862704B2 (en) 2013-12-20 2018-01-09 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
WO2015091931A1 (fr) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Dérivés d'oxindole à substituant azétidinyl substitué par pipéridyl, et leur utilisation pour le traitement de maladies liées à la vasopressine
WO2015173392A1 (fr) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Dérivés d'oxindole à substituant spiro à liaison co, et leur utilisation pour le traitement de maladies liées à la vasopressine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
DE102004033834A1 (de) * 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1773814B1 (fr) 2007-11-07
ATE377595T1 (de) 2007-11-15
CA2573404C (fr) 2010-01-12
US20090005397A1 (en) 2009-01-01
IL180654A0 (en) 2007-06-03
ES2297755T3 (es) 2008-05-01
US7951807B2 (en) 2011-05-31
US20110257194A1 (en) 2011-10-20
NZ552578A (en) 2010-06-25
EP1773814A2 (fr) 2007-04-18
BRPI0513281A (pt) 2008-05-06
KR20070051273A (ko) 2007-05-17
DE102004033834A1 (de) 2006-02-02
AU2005261867B2 (en) 2008-11-20
JP2008506647A (ja) 2008-03-06
KR100873319B1 (ko) 2008-12-10
DE502005001916D1 (de) 2007-12-20
AU2005261867A1 (en) 2006-01-19
CN101018778A (zh) 2007-08-15
WO2006005609A3 (fr) 2006-03-16
WO2006005609A2 (fr) 2006-01-19
MX2007000505A (es) 2007-06-25
US8338590B2 (en) 2012-12-25
CA2573404A1 (fr) 2006-01-19

Similar Documents

Publication Publication Date Title
IL180654A0 (en) Substituted oxindol derivatives and medicaments containing the same
JP3274865B2 (ja) ５−ｈｔレセプター拮抗物質としてのピペラジン誘導体
CA2394602A1 (fr) Nouveaux modulateurs de neurotransmission par dopamine
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
MEP5709A (en) 4-phenyl-pyridine derivatives
DE60130562D1 (de) Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
WO2000050398A3 (fr) Derives de pyridinyl et de phenyle
YU59901A (sh) Derivati 3-fenilpiridina i njihova primena kao antagonista nk-1 receptora
GEP20063958B (en) 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
DE69032020D1 (de) N-Substituierte 4-Pyrimidinamine und -Pyrimidindiamine, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
KR900016176A (ko) 피페라진 유도체
PE20000263A1 (es) Derivados ciclicos n-acilo de amina
BG106845A (en) New modulators of dopamine neurotransmission
BR9611300A (pt) Derivados de tropano em fusão suas preparações e uso
HRP20070529T3 (en) Imidazole derivatives as glutmate receptor antagonists
DE69622246T2 (de) Neue Naphthamid-Derivate und ihre therapeutische Verwendung als D3-Rezeptor Agonisten
HRP20080173T3 (en) IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF mGluR5 RECEPTOR MEDIATED DISORDERS
WO1999021848A3 (fr) Nouveau 1-(n'-(arylalkylaminoalkyl)aminoisoquinolines; nouvelle classe de ligands specifiques de sous-type de recepteur de dopamine
ATE323085T1 (de) Heterozyclische verbindungen mit affinität für den ht1 rezeptor und ihre therapeutische verwendung
ATE248802T1 (de) Neues amin-derivat, verfahren zur herstellung und dessen verwendung als anti-arrhythmisches mittel
NO20050147L (no) 1-fenylalkyl-piperaziner
WO2003068760A3 (fr) Composes presentant une affinite vis-a-vis des recepteurs du type 5ht1, et leur utilisation dans des traitements
ATE205212T1 (de) Substituierte 7,12-dioxabenzo(a)anthracenderivate,verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
WO2000012500A3 (fr) 2-aryl-4-[4-heteroaryl]piperazin-1-yl methylimidazoles: ligands pour le sous-type de recepteur d4 de la dopamine
IT1293806B1 (it) Ammidoalchilpiperazine attive sulle basse vie urinarie

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110713